AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for N-alpha-acetyltransferase 60

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H7X0

UPID:

NAA60_HUMAN

Alternative names:

Histone acetyltransferase type B protein 4; N-acetyltransferase 15; N-alpha-acetyltransferase F

Alternative UPACC:

Q9H7X0; B3KRQ0; B4DLZ0; B4DPZ8; B4DYC4; D3DUC2; E7EQ65; Q6IA31; Q6UX26

Background:

N-alpha-acetyltransferase 60, also known as Histone acetyltransferase type B protein 4, N-acetyltransferase 15, and N-alpha-acetyltransferase F, plays a pivotal role in protein modification. It specializes in the acetylation of N-terminal residues of transmembrane proteins, favoring those facing the cytosol. This enzyme exhibits specificity towards sequences starting with Met-Lys, Met-Val, Met-Ala, and Met-Met, and is essential for proper chromosomal segregation during anaphase. While its potential histone acetyltransferase activity is suggested, further evidence is required to confirm this function in vivo.

Therapeutic significance:

Understanding the role of N-alpha-acetyltransferase 60 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.